

September 21, 2023

TO: All Licensed New Hampshire Health Maintenance Organizations, Third Party Administrators ("TPAs"), Registered Administrative Services Providers with Respect to Health Insurance, Insurance Companies, and Health Service Corporations (together "Assessable Entities")

The records of either the New Hampshire Vaccine Association ("NHVA") or the New Hampshire Insurance Department ("NHID") reflect that you are likely an "Assessable Entity" under RSA 126-Q NHVA's governing statute. Assessable Entities are required to report on a quarterly basis all "Assessable Lives" to the NHVA. Assessable Lives are defined by statute to be "all children under 19 years of age residing in the state who have assessable coverage written or administered by an Assessable Entity."

The NHVA, working with Helms & Company, Inc. as administrator, facilitates the universal purchase of vaccines for New Hampshire children. By collecting payments from Assessable Entities and remitting funds to the State of New Hampshire it is possible for:

- physicians, clinics, and hospitals to receive state-supplied vaccines at no charge;
- New Hampshire children to have easy access to critical vaccines; and
- all payers to participate in one of the most efficient, cost-effective systems in the country for the purchase and distribution of childhood vaccines.

On September 20, 2023, NHVA's board ("Board") approved the 2024 calendar year assessment rate of \$12.50 per assessable life per month. 2024 assessment rate calculations will be made for amounts due on May 15, 2024, August 15, 2024, November 15, 2024, and February 15, 2025, for the measuring months of January through March, April through June, July through September, and October through December 2024, respectively.

For calendar years 2019-2023, the NHVA was able to use a portion of its reserves to stabilize the assessment rate at amounts below that of vaccine inflation. The increase in the assessment rate of \$4.00 per assessable life per month for 2024 is attributed to vaccine inflation, the commercialization of the COVID-19 vaccines, and higher costs for newly developed vaccines.

The rate of \$8.50 per assessable life per month, as set by the Board last year, remains in effect for assessment payments due November 15, 2023, and February 15, 2024. The Board advises assessable entities that its current best estimate of the calendar year 2025 rate is \$12.50 per assessable life per month. The 2025 assessment rate will be reviewed for final determination in September 2024. The NHVA self-reporting assessment system will automatically apply the correct rate for each quarter in the invoice it produces.

We continue to be grateful to the payer community for the timely filing of assessments throughout calendar year 2023, and your ongoing support of the NHVA. We invite you to review NHVA's Audited Financial Statements that are available on NHVA's website. Please reach out with any questions to info@nhvaccine.org.

Sincerely,

Patrick B. Miller, MPH NHVA Executive Director

Cc: NHVA Board of Directors